Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma

Summary

MAGNETO is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and teenagers aged 1-16 years with relapsed or refractory neuroblastoma. The study will assess the feasibility of generating the ATIMP (GD2 CAR T cells) and the safety of administering the ATIMP in patients with relapsed or refractory neuroblastoma.

Timeline

Start

2024-04-19

Primary completion

2026-12

Completion

2041-12

Drugs

Indications